Molecular Pharmaceutics
[ASAP] Construction of a <sup>124</sup>I‑Labeled Specific Antibody for the Noninvasive Detection of Mesothelin-Overexpressing Tumors
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00342
Molecular Pharmaceutics
[ASAP] Recent Advances in Targeted Nanotherapies for Ischemic Stroke
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00383
Molecular Pharmaceutics
[ASAP] Species Difference in Hydrolysis of an Ester-Type Prodrug of Levodopa in Human and Animal Plasma: Different Contributions of Alpha‑1 Acid Glycoprotein
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00598
Molecular Pharmaceutics
[ASAP] Design of ROS-Responsive Hyaluronic Acid–Methotrexate Conjugates for Synergistic Chemo-Photothermal Therapy for Cancer
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00472
Molecular Pharmaceutics
[ASAP] Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T‑cell Distribution
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00361
Molecular Pharmaceutics
[ASAP] Differential Surface Adsorption Phenomena for Conventional and Novel Surfactants Correlates with Changes in Interfacial mAb Stabilization
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00152
Molecular Pharmaceutics
[ASAP] Influence of Water on Amorphous Lidocaine
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00339
Molecular Pharmaceutics
[ASAP] Nanoparticle Fraught Liposomes: A Platform for Increased Antibiotic Selectivity in Multidrug Resistant Bacteria
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00258
Molecular Pharmaceutics
[ASAP] Emerging Nanotechnologies and Microbiome Engineering for the Treatment of Inflammatory Bowel Disease
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00222
Molecular Pharmaceutics
[ASAP] Immune-Cell-Derived Exosomes for Cancer Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00407